
Hematology-OncologyBPDCNdrug resistance
Decoding Resistance to Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm: The Role of TXNRD1 and TET2 Mutations
By MedXY|Jul 9, 2026
This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.